Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Farmers Insurance
Boehringer Ingelheim
UBS
Cipla
Argus Health
Daiichi Sankyo
McKinsey
Merck

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,974,590

« Back to Dashboard

Which drugs does patent 6,974,590 protect, and when does it expire?


Patent 6,974,590 protects FENTORA and is included in one NDA. There has been one Paragraph IV challenge on Fentora.

This patent has thirty-two patent family members in twelve countries.

Summary for Patent: 6,974,590

Title: Sublingual buccal effervescent
Abstract:A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Inventor(s): Pather; Sathasivan Indiran (Plymouth, MN), Khankari; Rajendra K. (Maple Grove, MN), Eichman; Jonathan D. (Ann Arbor, MI), Robinson; Joseph R. (Madison, WI), Hontz; John (Plymouth, MN)
Assignee: Cima Labs Inc. (Minneapolis, MN)
Application Number:10/080,016
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-001Sep 25, 2006RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-002Sep 25, 2006RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-006Mar 2, 2007DISCNYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-003Sep 25, 2006RXYesYes► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-004Sep 25, 2006RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
CephalonFENTORAfentanyl citrateTABLET;BUCCAL, SUBLINGUAL021947-005Sep 25, 2006RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,974,590

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,764,696 Effervescent drug delivery system for oral administration► Subscribe
6,200,604 Sublingual buccal effervescent► Subscribe
8,728,441Sublingual buccal effervescent► Subscribe
8,753,611Sublingual buccal effervescent► Subscribe
6,641,838 Effervescent drug delivery system for oral administration► Subscribe
6,509,036 Effervescent drug delivery system for oral administration► Subscribe
8,765,100Transmucosal effervescent► Subscribe
6,576,250 Pharmaceutical compositions for rectal and vaginal administration► Subscribe
8,802,130Sublingual buccal effervescent► Subscribe
6,391,335 Effervescent drug delivery system for oral administration► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,974,590

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1419765► Subscribe
Portugal1417959► Subscribe
Portugal1082106► Subscribe
Japan2002543109► Subscribe
Japan4954170► Subscribe
Japan2009029829► Subscribe
Japan4789324► Subscribe
Japan2002540141► Subscribe
Hong Kong1130691► Subscribe
Spain2383478► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Queensland Health
McKesson
US Army
Cipla
Farmers Insurance
Merck
US Department of Justice
Citi
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot